A startup working on products to treat skin conditions and enhance the delivery of pharmaceuticals through the skin has raised $2 million of a potential $3 million, according to U.S. Securities and Exchange Commission filings.
Convoy Therapeutics’ proprietary Skin Permeating and Cell Entering (SPACE) technology is a nonpolar, nontoxic peptide sequence that the company says demonstrates skin and cell permeation without altering the skin structure. Getting macromolecules such as siRNA, proteins, peptides and cytokines to penetrate the skin and enter cells once inside the body has long been a challenge in the development of transdermal drug-delivery platforms.
CEO John Muraski was not available for comment, but according to Convoy’s website, the company is in the early stages of development and is actively seeking major development partners to sub-license technology. SPACE can be coupled with existing therapeutics as a drug delivery mechanism, but the company is initially focused on developing treatments for psoriasis and eczema, with the long-term goal of using siRNA delivery to treat malignant melanoma, its website says.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A subsidiary of ACTUS Biotechnologies, Convoy was formed in 2011 and is based in Las Vegas.
